Bessler Robert sold $9.1M of LFST (indirect holdings)

Bessler Robert sold 894,337 indirectly-held shares of LifeStance Health Group, Inc. (LFST) at $10.13 ($9.06M total) across 2 trades on 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bessler Robert
Published Jun 30, 2026, 8:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LFST
Neutral
medium confidence
Mentioned
$LFST
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LFSTNeutralLow
01

Why it matters

Provides a concrete, newly filed datapoint on insider selling size, price, and post-transaction holdings, which can affect short-term sentiment but not fundamentals by itself.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 framing generally limits the signal strength.

03

What to watch

The disclosure is indirect holdings and pre-arranged; without additional context (e.g., total insider activity, other filings), directional inference is weak.

Relevance 5/10Novelty 5/10Timing: Filed 2026-06-30; transaction dated 2026-06-26 (after-hours/next-session read-through).

Background

The article is an SEC Form 4 insider transaction: director Robert Bessler sold LifeStance Health Group shares via an open-market sale under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$LFSTNeutralMedium confidence
Context

LifeStance Health Group director Robert Bessler sold 894,337 shares in an open-market transaction under a 10b5-1 plan at $10.13.

Expected impact

Likely limited immediate impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a primary Form 4 disclosure with transaction size and price, but it explicitly states a pre-arranged 10b5-1 plan, reducing interpretive weight.

Market effects

No sector-level read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, large sales can coincide with personal liquidity needs or risk management, which some traders may still interpret as caution.

Key entities

  • LifeStance Health Group, Inc.

    Subject of the Form 4 insider transaction; director Robert Bessler sold shares under a 10b5-1 plan.

  • Robert Bessler

    Director who executed the open-market sale; transaction disclosed on SEC EDGAR.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LFSTMed

BMO raises Lifestance Health stock price target on strong results

BMO Capital raised its price target on Lifestance Health (LFST) to $16.00, citing strong Q3 results. Revenue beat estimates by 5.6%, and EBITDA exceeded by 23.6%. The company raised its full-year outlook, but expects a sequential EBITDA decline due to reinvestment. LFST trades at $13.43 with a $5.1B market cap. The company also announced Q3 2026 earnings, surpassing expectations with a 25% revenue increase.

$LFSTMed

What LifeStance Health Group (LFST) Said on Its Q3 Earnings Call

LifeStance Health Group (LFST) forecasted Q4 revenue of $446M-$466M and adjusted EBITDA of $56M-$64M. The company expects a 1-2% reduction in 2027 revenue growth due to a new electronic health record system. LifeStance expanded specialty services, including TMS and SPRAVATO, and plans to continue acquisitions and center openings. Management expects specialty services revenue to reach $70M this year, up from $50M in 2025.

$LFSTMed

LifeStance Health Group Inc (LFST) (Q3 2026) Earnings Call Highlights: Revenue Jumps 25%

LifeStance Health (LFST) reported 25% revenue growth in Q3 2026. The company expects EHR implementation to reduce 2027 revenue growth by 1-2% and cost $20-30M. Clinician retention is stable, but new clinician retention is low. Q4 adjusted EBITDA guidance suggests a sequential decline due to planned investments. Specialty services, including Spravato, are growing but face variable payer reimbursement. Management remains optimistic about long-term margin expansion and clinician growth.

$LFSTHighAI 8/10

LifeStance (LFST) Q3 2026 Earnings Call Transcript

LifeStance (LFST) reported Q3 2026 revenue growth of 25% to $456M, driven by increased visit volumes and higher revenue per visit. The company expanded its clinician base by 11% and opened 8 new centers. It also raised full-year revenue guidance to $1.741B-$1.761B. LifeStance highlighted strong results in specialty services for treatment-resistant depression and plans to invest in strategic priorities. The company expects temporary revenue growth impact in 2027 due to EHR implementation.

$LFSTMed

LifeStance Health: Q3 Earnings Snapshot

LifeStance Health Group Inc. (LFST) reported Q3 net income of $22.4M, or 6 cents per share, beating estimates. Revenue was $455.9M, also exceeding forecasts. The company expects Q4 revenue of $446M-$466M and full-year revenue of $1.74B-$1.76B.